Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Calsed (7S,9R)-9-amino-7- [(2S,4S,5R)-4,5...

Synonyms: Calsed (TN), CHEMBL481958, SureCN491010, SM-5887, LS-94007, ...

This record was replaced with 3035016.

Morisada, S. et al., Takagi, T. et al., Morisada, S. et al., Osaki, S. et al., Suzuki, T. et al., et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxytetrahydropyran-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione

On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy [1].
The general toxicological investigations uniformly indicated lower toxicity in the SM-5887 group than in the doxorubicin group at equivalent dosages [2].
A new anthracycline derivative, SM5887, in combination with commonly used anticancer agents was evaluated against T-cell leukemia MOLT-3 and human osteosarcoma MG-63 cell lines in culture [3].
The maximum tolerated doses (MTD) were estimated to be 25 mg/kg for SM-5887 and 12.5 mg/kg for ADR (no death or body weight loss of more than 3 g occurred) [4].
The antitumor effects of SM-5887, a totally synthetic 9-aminoanthracycline derivative, were evaluated in six murine experimental tumor systems (P388, Ehrlich carcinoma, sarcoma 180, Lewis lung carcinoma, B16 melanoma and colon 38) and nine human tumor-nude mouse systems (one breast cancer, two lung cancers and six gastric cancers) [5].

High impact information on (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxytetrahydropyran-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione

The effects of SM5887 in combination with 5-fluorouracil, cytarabine or vincristine may be variable, depending on cell lines [3].
Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines [3].
The acute toxic signs observed after SM-5887 administration were body weight decrease, ataxia, hair loss, and myelosuppression [4].
In addition, the 10-day-interval repeated iv treatments with SM-5887 at the MTD (25 mg/kg) resulted in remarkably potent antitumor effects (including complete regression) against human gastric cancer, 4-1ST, implanted in nude mice without enhancement of toxic effects [5].
The gene transfer of AdIkappaBalpha decreased IC50 from 12.0 to 2.2 nM on paclitaxel and increased IC50 from 0.27 to 16.0 microM on SM5887 compared with the transfer of control gene, AdLacZ [6].

Analytical, diagnostic and therapeutic context of (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxytetrahydropyran-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione

Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts [5].
SM-5887 was also effective against ip-inoculated P388 by oral administration as well as iv injection [5].

References

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Noda, T., Watanabe, T., Kohda, A., Hosokawa, S., Suzuki, T. Investigational new drugs. (1998) [Pubmed]
Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Suzuki, T., Minamide, S., Iwasaki, T., Yamamoto, H., Kanda, H. Investigational new drugs. (1997) [Pubmed]
Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines. Takagi, T., Yazawa, Y., Suzuki, K., Yamauchi, Y., Kano, Y. Investigational new drugs. (1996) [Pubmed]
Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Morisada, S., Yanagi, Y., Kashiwazaki, Y., Fukui, M. Jpn. J. Cancer Res. (1989) [Pubmed]
Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Morisada, S., Yanagi, Y., Noguchi, T., Kashiwazaki, Y., Fukui, M. Jpn. J. Cancer Res. (1989) [Pubmed]
Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell. Osaki, S., Nakanishi, Y., Takayama, K., Pei, X.H., Ueno, H., Hara, N. J. Exp. Clin. Cancer Res. (2003) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.